Search Results - "SAHEBI, F"

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma by Herrera, A.F., Palmer, J., Martin, P., Armenian, S., Tsai, N.-C., Kennedy, N., Sahebi, F., Cao, T., Budde, L.E., Mei, M., Siddiqi, T., Popplewell, L., Rosen, S.T., Kwak, L.W., Nademanee, A., Forman, S.J., Chen, R.

“…We previously demonstrated that brentuximab vedotin (BV) used as second-line therapy in patients with Hodgkin lymphoma is a tolerable and effective bridge to…”
Get full text

Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma by Sahebi, F, Iacobelli, S, Biezen, A V, Volin, L, Dreger, P, Michallet, M, Ljungman, P T, de Witte, T, Henseler, A, Schaap, N P M, López-Corral, L, Poire, X, Passweg, J, Hamljadi, R-M, Thomas, S H, Schonland, S, Gahrton, G, Morris, C, KrÖger, N, Garderet, L

“…We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients…”
Get full text

Late Lung and Thyroid Toxicities From Total Marrow and Lymphoid Irradiation for Patients Undergoing Hematopoietic Stem Cell Transplantation by Kim, D.H, Frankel, P, Palmer, J, Somlo, G, Rosenthal, J, Stein, A.S, Sahebi, F, Schultheiss, T.E, Forman, S.J, Wong, J.Y

Get full text

Phase 1 Dose Escalation Trial of Total Marrow and Lymphoid Irradiation (TMLI) Using Helical Tomotherapy Combined With Etoposide (VP16) and Cyclophosphamide (CY) in Patients With Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) by Wong, J.Y, Stein, A, Palmer, J.M, Liu, A, O'Donnell, M, Schultheiss, T, Radany, E, Snyder, D.S, Tsai, N, Parker, P, Farol, L, Spielberger, R, Sahebi, F, Murata-Collins, J, Senitzer, D, Forman, S

Get full text

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial by STEWART, A. Keith, VESCIO, Robert, STIFF, Pat, MEHARCHARD, Jacinta, SCHLOSSMAN, Robert, BROWN, Randy, TULLY, Heather, BENYUNES, Mark, JACOBS, Cindy, BERENSON, Ronald, WHITE, Michael, DIPERSIO, John, SCHILLER, Gary, ANDERSON, Kenneth C, BERENSON, James, BALLESTER, Oscar, NOGA, Stephen, RUGO, Hope, FREYTES, Cesar, STADTMAUER, Edward, TARANTOLO, Stefano, SAHEBI, Firoozeh

“…Although high-dose chemotherapy supported by autologous peripheral-blood progenitor-cell (PBPC) transplantation improves response rates and survival for…”
Get full text

Total Marrow Irradiation (TMI) with Helical Tomotherapy and Peripheral Blood Progenitor Cell Rescue (PBPC) Following high-Dose Melphalan (Mel) and PBPC as Part of Tandem Autologous Transplant (TAT) for Patients with Multiple Myeloma by Somlo, G, Liu, A, Schultheiss, T.E, Frankel, P, Spielberger, R.T, Popplewell, L, Zhou, K, Hawkins, D, Krishnan, A.Y, Sahebi, F, Kogut, N, Parker, P.M, Stein, A, Snyder, D, Forman, S.J, Wong, J.Y.C

Get full text

Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD by Rodriguez, R, Nademanee, A, Palmer, J M, Parker, P, Nakamura, R, Snyder, D, Pullarkat, V, Zain, J, Smith, E, Sahebi, F, Patane, K, Senitzer, D, Chang, K, Forman, S J

Get full text

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma by SAHEBI, F, SPIELBERGER, R, POPPLEWELL, L, FRANKEL, P, RUEL, C, TIN, R, ILIEVA, P, FORMAN, S. J, SOMLO, G, KOGUT, N. M, FUNG, H, FALK, P. M, PARKER, P, KRISHNAN, A, RODRIGUEZ, R, NAKAMURA, R, NADEMANEE, A

“…Although autologous stem cell transplant is an effective therapy for patients with multiple myeloma and extends progression-free survival (PFS) and overall…”
Get full text

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies by RODRIGUEZ, R, PARKER, P, COHEN, S, SOMLO, G, ANGELOPOULOU, M, AL-KADHIMI, Z, FALK, P. M, SPIELBERGER, R, KOGUT, N, SAHEBI, F, SENITZER, D, SLOVAK, M, NADEMANEE, A, SCHRIBER, J, FORMAN, S. J, SMITH, D, O'DONNELL, M. R, STEIN, A, SNYDER, D. S, FUNG, H. C, KRISHNAN, A. Y, POPPLEWELL, L

“…In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination…”
Get full text

Phase I Study of Bortezomib, Fludarabine, and Melphalan, with or without Total Marrow Irradiation as Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Relapsed/Refractory Multiple Myeloma by Ladbury, C.J., Sanchez, J.F., Chowdhury, A., Palmer, J., Liu, A., Stein, A., Htut, M., Farol, L., Cai, J.L., Somlo, G., Rosenzweig, M., Wong, J.Y.C., Sahebi, F.

“…Though outcomes of patients with multiple myeloma (MM) have improved, cure remains elusive. Allogeneic hematopoietic stem cell transplantation (allo-sCT) is…”
Get full text

Phase II Trial of TMLI 20 Gy in Combination with Cyclophosphamide and Etoposide in Patients with Poor-Risk Acute Leukemia by Wong, J.Y.C., Monzr, A.M., Salhotra, A., Dandapani, S.V., Wang, Y., Palmer, J., Han, C., Liu, A., Radany, E.H., Aldoss, I., Ali, H., Farol, L., Sahebi, F., Spielberger, R., Marcucci, G., Nakamura, R., Smith, E., Hui, S.K., Forman, S.J., Stein, A.

“…Patients with relapsed or refractory (R/R) acute leukemia have a poor prognosis with current hematopoietic cell transplant (HCT) options. Total marrow and…”
Get full text

First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed and Refractory (R/R) Acute Leukemia by Wong, J.Y.C., Monzr, A.M., Sahebi, F., Dandapani, S.V., Yamauchi, D.M., Salhotra, A., Adhikarla, V., Ali, H., Poku, E., Yang, D., Han, C., Liu, A., Mokhtari, S., Wu, A., Yazaki, P., Shively, J.E., Hui, S.K., Smith, E., Stein, A.

“…Patients with R/R acute leukemia after allogeneic hematopoietic cell transplant (alloHCT) have a dismal prognosis with 3-year survival rates of < 20%. To…”
Get full text

PO-1171 Ten-year follow-up of tandem autologous transplantation with total marrow irradiation for myeloma by Ladbury, C., Rincon, A., Song, J., Armenian, S., Liu, A., Spielberger, R., Popplewell, L., Sahebi, F., Parker, P., Forman, S., Snyder, D., Dagis, A., Frankel, P., Yang, D., Wong, J., Somlo, G.

Get full text

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome by Fung, H.C, Stein, A, Slovak, M.L, O’Donnell, M.R, Snyder, D.S, Cohen, S, Smith, D, Krishnan, A, Spielberger, R, Bhatia, R, Bhatia, S, Falk, P, Molina, A, Nademanee, A, Parker, P, Rodriguez, R, Rosenthal, J, Sweetman, R, Kogut, N, Sahebi, F, Popplewell, L, Vora, N, Somlo, G, Margolin, K, Chow, W, Smith, E, Forman, S.J

“…The prognosis of patients with primary refractory acute myelogenous leukemia (AML) is poor. Our initial report suggested that some patients could achieve…”
Get full text

Mucormycosis of the vulva following bone marrow transplantation by NOMURA, J, RUSKIN, J, SAHEBI, F, KOGUT, N, FALK, P. M

“…Mucormycosis is uncommon in bone marrow transplant recipients. Primary cutaneous mucor in any setting is unusual. It may mimic necrotizing bacterial infection…”
Get full text

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma by Krishnan, A, Kapoor, P, Palmer, J M, Tsai, N-C, Kumar, S, Lonial, S, Htut, M, Karanes, C, Nathwani, N, Rosenzweig, M, Sahebi, F, Somlo, G, Duarte, L, Sanchez, J F, Auclair, D, Forman, S J, Berdeja, J G

“…In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32…”
Get full text

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma by Maloney, David G., Molina, Arthur J., Sahebi, Firoozeh, Stockerl-Goldstein, Keith E., Sandmaier, Brenda M., Bensinger, William, Storer, Barry, Hegenbart, Ute, Somlo, George, Chauncey, Thomas, Bruno, Benedetto, Appelbaum, Frederick R., Blume, Karl G., Forman, Stephen J., McSweeney, Peter, Storb, Rainer

“…The full potential of a graft-versusmyeloma effect after allogeneic hematopoietic cell transplantation (HCT) for patients with multiple myeloma (MM) has not…”
Get full text

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered By Tomotherapy Combined With Etoposide and Cyclophosphamide; an Allogeneic HCT Preparative Regimen for Patients With Advanced Leukemia by Stein, A.S, Wong, J, O'Donnell, M.R, Synder, D.S, Palmer, J.M, Tsai, N.-C, Parker, P, Farol, L, Spielberger, R, Sahebi, F, Kogut, N, Forman, S

Get full text

Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen by Sahebi, F, Copelan, E, Crilley, P, Bolwell, B, Avalos, B, Klein, J, Territo, M, Gajewski, J

“…This study reviews results of a radiation-free preparative regimen consisting of busulfan and cyclophosphamide in 65 unrelated allogeneic bone marrow…”
Get more information

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma by Nademanee, Auayporn, Forman, Stephen, Molina, Arturo, Fung, Henry, Smith, David, Dagis, Andy, Kwok, Cheuk, Yamauchi, Dave, Anderson, Anne-Line, Falk, Peter, Krishnan, Amrita, Kirschbaum, Mark, Kogut, Neil, Nakamura, Ryotaro, O'Donnell, Margaret, Parker, Pablo, Popplewell, Leslie, Pullarkat, Vinod, Rodriguez, Roberto, Sahebi, Firoozeh, Smith, Eileen, Snyder, David, Stein, Anthony, Spielberger, Ricardo, Zain, Jasmine, White, Christine, Raubitschek, Andrew

“…We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and…”
Get full text